Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Anixa Biosciences (NASDAQ: ANIX) will present at the H.C. Wainwright 28th Annual Global Investment Conference, with a webcast available starting 7:00 AM ET on September 11, 2026, ahead of the conference dates of September 14–16, 2026.
According to Anixa, the presentation by Chairman and CEO Dr. Amit Kumar will review the company’s breast cancer vaccine, which completed a Phase 1 trial meeting all primary endpoints, including safety, with protocol-defined immune responses in 74% of participants, and for which Phase 2 preparations are underway. Dr. Kumar will also discuss the ovarian cancer CAR-T therapy lira-cel, now at the fifth and highest dose cohort evaluated to date with lymphodepletion introduced, where no dose-limiting toxicities have been observed and four patients have surpassed one year of survival, the longest at approximately 28 months.
Anixa Biosciences (NASDAQ: ANIX) reported that IP Australia issued a Notice of Acceptance for a patent covering its breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. Titled “Vaccine Adjuvants and Formulations,” the patent protects Anixa’s preventive and therapeutic breast cancer vaccine approach in Australia.
The patent complements existing coverage in the United States, Europe, China, Japan and other regions, expanding Anixa’s global intellectual property estate. A recently completed Phase 1 trial at Cleveland Clinic, funded by the U.S. Department of Defense, met major primary endpoints, showed safety and tolerability, and generated protocol-defined immune responses in over 74% of participants.
Anixa Biosciences (NASDAQ: ANIX) reported treatment of the first patient in cohort 5 of its Phase 1 FSHR-targeted CAR-T/CER-T trial for recurrent ovarian cancer at Moffitt Cancer Center.
The study has escalated to 1×10⁷ CAR-positive cells/kg, with no dose-limiting toxicities observed to date and five patients surviving 13–28 months post-treatment.
Anixa Biosciences (NASDAQ: ANIX) received its first Korean composition-of-matter patent (No. 10-2960889) for its breast cancer vaccine, granting exclusive protection in South Korea through 2040.
The patent, licensed from Cleveland Clinic, extends Anixa’s global IP estate and supports ongoing U.S. clinical development after a Phase 1 trial showed immune responses in 74% of participants.
Anixa Biosciences (NASDAQ: ANIX) reported updated clinical data for its breast cancer vaccine and ovarian cancer CAR‑T therapy presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium.
The completed Phase 1 breast cancer vaccine trial met all major primary endpoints, showed the vaccine was safe and well tolerated at the maximum tolerated dose, and induced protocol-defined immune responses in 74% of participants. The ongoing Phase 1 trial of ovarian cancer CAR‑T therapy lira-cel reported survival observations of multiple patients living over one year after treatment. Both programs are being developed with Cleveland Clinic and Moffitt Cancer Center, and presentations are available on Anixa's investor events webpage.
Anixa Biosciences (NASDAQ: ANIX) will present two clinical-stage immunotherapy programs at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium on June 22–23, 2026.
Presentations cover the Phase 1 ovarian cancer CAR‑T therapy lira‑cel and a breast cancer vaccine with all major primary endpoints met and protocol-defined immune responses in 74% of participants.
Anixa Biosciences (NASDAQ: ANIX) received a Canadian Intellectual Property Office Notice of Allowance for a patent covering key aspects of its AMHR2-targeted ovarian cancer vaccine technology, exclusively licensed from Cleveland Clinic.
The allowance expands protection beyond an existing U.S. patent and supports Anixa’s broader cancer vaccine platform, including a breast cancer vaccine whose Phase 1 trial met all primary endpoints.
Anixa Biosciences (NASDAQ: ANIX) reported updated survival and safety observations from its ongoing Phase 1 trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer.
Multiple patients have lived well beyond the typical three‑to‑four‑month median survival, and preliminary safety data show no dose‑limiting toxicities, ICANS or significant CRS in the first three dose cohorts.
Anixa Biosciences (NASDAQ: ANIX) reported updated survival and safety data from its ongoing Phase 1 trial of lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Multiple patients lived well beyond the typical 3–4 month median survival, with no dose-limiting toxicities, ICANS or significant CRS observed so far.
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar will be interviewed on the RedChip Small Stocks, Big Money™ show airing on Bloomberg TV Saturday, May 2, 2026 at 7pm ET. The interview will review the company, its capital‑efficient model, the breast cancer vaccine Phase 1 results showing protocol‑defined immune responses in 74% of participants, and ongoing positive survival data for ovarian CAR‑T therapy lira‑cel in a Phase 1 trial. Bloomberg TV reaches an estimated 73 million U.S. homes; the segment is also available online via Anixa’s website.